Capponi A M, Gourjon M, Vallotton M B
Circ Res. 1977 May;40(5 Suppl 1):I89-93.
Mechanisms by which beta-blocking agents decrease blood pressure and suppress renin release are incompletely understood. We previously demonstrated that renin release by kidney slices may be increased by beta-adrenergic agonists, and the present communication contains our results on the effects of 15 beta-blocking agents and angiotensin II on isoproterenol-stimulated renin release. None of the beta-blocking compounds inhibited basal renin release. Each agent was evaluated at concentrations ranging from 10-8 to 10-5 m and three different dose-response curve patterns were observed: (1) Metoprolol, acebutolol, labetalol, and d-propranolol had no effect on isoproterenol-stimulated renin release at any concentration, whereas pindolol and bufuralol demonstrated minimal inhibition at 10-5 m only. (2) Isoproterenol stimulation was completely inhibited when dl- or l-propranolol, alprenolol, and sotalol were administered at doses ranging between 5 x 10-6 and 10-6 m; but greater concentration of these agents resulted in reappearance of the isoproterenol response. (3) Dose-related inhibition was observed with practolol, oxprenolol, timolol, nadolol, and atenolol at concentrations ranging from 10-8 to 10-5 m. Basal renin release was significantly (P is less than 0.01) inhibited by angiotensin II at 10-6 m, which also inhibited isoproterenol-stimulated renin release in a dose-related fashion. [Sar1, Ala8] angiotensin II had no direct effects on either basal or isoproterenol-stimulated renin release, but blocked the inhibitory action of angiotensin II on these parameters.
There are three different effects of beta-blocking agents on isoproterenol-stimulated renin release which can only partially be explained by their presently ascribed pharmacological properties. (Beta 1- and beta2-agonists, intrinsic sympathomimetic activity, membrane-stabilizing actions). Angiotensin II inhibition of renin release appears to be functionally related to adrenergic pathways.
β受体阻滞剂降低血压和抑制肾素释放的机制尚未完全明确。我们之前证明,β肾上腺素能激动剂可增加肾切片的肾素释放,本文包含了我们关于15种β受体阻滞剂和血管紧张素II对异丙肾上腺素刺激的肾素释放影响的研究结果。没有一种β受体阻滞剂化合物能抑制基础肾素释放。每种药物在10⁻⁸至10⁻⁵m的浓度范围内进行评估,观察到三种不同的剂量反应曲线模式:(1)美托洛尔、醋丁洛尔、拉贝洛尔和d-普萘洛尔在任何浓度下对异丙肾上腺素刺激的肾素释放均无影响,而吲哚洛尔和布呋洛尔仅在10⁻⁵m时表现出最小程度的抑制。(2)当给予dl-或l-普萘洛尔、阿普洛尔和索他洛尔,剂量在5×10⁻⁶至10⁻⁶m之间时,异丙肾上腺素刺激被完全抑制;但这些药物浓度更高时,异丙肾上腺素反应会再次出现。(3)在10⁻⁸至10⁻⁵m的浓度范围内,醋氨心安、氧烯洛尔、噻吗洛尔、纳多洛尔和阿替洛尔呈现剂量相关的抑制作用。血管紧张素II在10⁻⁶m时可显著(P<0.01)抑制基础肾素释放,并且也以剂量相关的方式抑制异丙肾上腺素刺激的肾素释放。[Sar¹,Ala⁸]血管紧张素II对基础或异丙肾上腺素刺激的肾素释放均无直接影响,但可阻断血管紧张素II对这些参数的抑制作用。
β受体阻滞剂对异丙肾上腺素刺激的肾素释放有三种不同的作用,目前归因于它们的药理学特性只能部分解释这些作用。(β₁和β₂激动剂、内在拟交感活性、膜稳定作用)。血管紧张素II对肾素释放的抑制似乎在功能上与肾上腺素能途径相关。